MARKET

AFMD

AFMD

Affimed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.65
-0.18
-2.64%
After Hours: 6.74 +0.09 +1.35% 19:44 07/30 EDT
OPEN
6.80
PREV CLOSE
6.83
HIGH
6.97
LOW
6.63
VOLUME
822.61K
TURNOVER
--
52 WEEK HIGH
11.74
52 WEEK LOW
3.070
MARKET CAP
791.04M
P/E (TTM)
-15.1550
1D
5D
1M
3M
1Y
5Y
Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors
AFM24 is an innate cell engager with a novel and distinctive mechanism of action, designed to address the need of broader patient populations than current EGFR-targeting treatments.Preclinical data demonstrate AFM24’s activation of the innate immune system...
GlobeNewswire · 1d ago
15 Stocks that Will Double In 2021
In this article, we discuss the 15 stocks that will double in 2021. If you want to skip our detailed analysis of these stocks, go directly to the 5 Stocks that Will Double In 2021. The economy of 2020 was closely linked to the COVID-19 pandemic. However, t...
Insider Monkey · 2d ago
NRXP, PDD, ACOR and IPA among after-hours movers
Gainers: [[NRXP]] +10.1%. [[PDD]] +6.6%. [[TLSA]] +6.3%. [[AFMD]] +4.4%. [[UXIN]] +3.8%.Losers: [[ACOR]] -3.8%. [[IPA]] -2.8%. [[SNCR]] -2.5%. [[PRVB]] -2.3%. [[INCY]] -3.3%.
Seekingalpha · 07/23 21:40
Hedge Funds Are Crazy About Affimed NV (AFMD)
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshl...
Insider Monkey · 07/19 23:15
Analyzing Affimed's Unusual Options Activity
Shares of Affimed (NASDAQ:AFMD) saw some unusual options activity on Tuesday. Following the unusual option alert, the stock price moved down to $6.77.
Benzinga · 07/13 15:17
Unusual Options Activity Insight: Affimed
On Thursday, shares of Affimed (NASDAQ:AFMD) saw unusual options activity. After the option alert, the stock price moved down to $7.49.
Benzinga · 07/01 15:42
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30)
Benzinga · 07/01 12:06
Affimed posts Q1 topline beat, provides cash runway update
Affimed (AFMD) posted first-quarter revenue that beat Wall Street estimates, and said that it expects the company's cash and cash equivalents to support operations into the second half of 2023.The company's
Seekingalpha · 07/01 11:33
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AFMD. Analyze the recent business situations of Affimed through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AFMD stock price target is 15.10 with a high estimate of 18.12 and a low estimate of 13.09.
EPS
Institutional Holdings
Institutions: 154
Institutional Holdings: 83.68M
% Owned: 70.35%
Shares Outstanding: 118.95M
TypeInstitutionsShares
Increased
61
13.90M
New
20
12.49M
Decreased
32
6.17M
Sold Out
13
933.04K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.07%
Pharmaceuticals & Medical Research
-0.24%
Key Executives
Chairman - Supervisory/Independent Director
Thomas Hecht
Chief Executive Officer/Management Board
Adi Hoess
Chief Financial Officer/Management Board
Angus Smith
Chief Operating Officer/Management Board
Wolfgang Fischer
Chief Scientific Officer/Management Board
Arndt Schottelius
Management Board
Andreas Harstrick
Management Board
Denise Mueller
Independent Director/Supervisory Board
Bernhard Ehmer
Independent Director/Supervisory Board
Ulrich Grau
Independent Director/Supervisory Board
Mathieu Simon
Independent Director/Supervisory Board
Ferdinand Verdonck
Supervisory Board
Annalisa Jenkins
Supervisory Board
Uta Kemmerich-Keil
Supervisory Board
Harry Welten
No Data
  • All
  • Financials
  • Insiders
More
About AFMD
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Webull offers kinds of Affimed NV stock information, including NASDAQ:AFMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AFMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AFMD stock methods without spending real money on the virtual paper trading platform.